Cited 335 times in
Entecavir Therapy for up to 96 Weeks in Patients With HBeAg-Positive Chronic Hepatitis B
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 한광협 | - |
dc.date.accessioned | 2014-12-21T16:37:33Z | - |
dc.date.available | 2014-12-21T16:37:33Z | - |
dc.date.issued | 2007 | - |
dc.identifier.issn | 0016-5085 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/96042 | - |
dc.description.abstract | BACKGROUND & AIMS: Entecavir demonstrated superior benefit to lamivudine at 48 weeks in nucleoside-naive patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB). We evaluated continued entecavir and lamivudine treatment through 96 weeks. METHODS: 709 HBeAg-positive CHB patients were randomized to entecavir 0.5 mg (n = 354) or lamivudine 100 mg (n = 355) once daily. At week 52, protocol-defined virologic responders could continue blinded treatment for up to 96 weeks. Patients continuing in year 2 (entecavir, n = 243; lamivudine, n = 164) were assessed for serum hepatitis B virus (HBV) DNA, alanine aminotransferase (ALT) normalization, HBeAg seroconversion, and safety. Cumulative confirmed proportions of all treated patients who achieved these responses were also analyzed. RESULTS: Among patients treated in year 2, 74% of entecavir-treated versus 37% of lamivudine-treated patients achieved HBV DNA <300 copies/mL by polymerase chain reaction (PCR), and 79% of entecavir-treated versus 68% of lamivudine-treated patients normalized ALT levels. Similar proportions of entecavir-treated and lamivudine-treated patients achieved HBeAg seroconversion (11% vs 12%, respectively). Higher proportions of entecavir-treated than lamivudine-treated patients achieved cumulative confirmed HBV DNA <300 copies/mL by PCR (80% vs 39%; P < .0001) and ALT normalization (87% vs 79%; P = .0056) through 96 weeks. Cumulative confirmed HBeAg seroconversion occurred in 31% of entecavir-treated versus 25% of lamivudine-treated patients (P = NS). Through 96 weeks, no patient experienced virologic breakthrough due to entecavir resistance. The safety profile was comparable in both groups. CONCLUSIONS: Entecavir treatment through 96 weeks results in continued benefit for patients with HBeAg-positive CHB. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 1437~1444 | - |
dc.relation.isPartOf | GASTROENTEROLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Alanine Transaminase/blood | - |
dc.subject.MESH | Antiviral Agents/adverse effects | - |
dc.subject.MESH | Antiviral Agents/therapeutic use* | - |
dc.subject.MESH | DNA, Viral/blood | - |
dc.subject.MESH | Dose-Response Relationship, Drug | - |
dc.subject.MESH | Double-Blind Method | - |
dc.subject.MESH | Guanine/adverse effects | - |
dc.subject.MESH | Guanine/analogs & derivatives* | - |
dc.subject.MESH | Guanine/therapeutic use | - |
dc.subject.MESH | Hepatitis B e Antigens/blood* | - |
dc.subject.MESH | Hepatitis B virus/genetics | - |
dc.subject.MESH | Hepatitis B, Chronic/drug therapy* | - |
dc.subject.MESH | Hepatitis B, Chronic/immunology* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Lamivudine/adverse effects | - |
dc.subject.MESH | Lamivudine/therapeutic use | - |
dc.title | Entecavir Therapy for up to 96 Weeks in Patients With HBeAg-Positive Chronic Hepatitis B | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Robert G. Gish | - |
dc.contributor.googleauthor | Anna S. Lok | - |
dc.contributor.googleauthor | Helena Brett–Smit | - |
dc.contributor.googleauthor | Richard Colonno | - |
dc.contributor.googleauthor | Joanna Yang | - |
dc.contributor.googleauthor | Melissa Harris | - |
dc.contributor.googleauthor | Shou–Dong Lee | - |
dc.contributor.googleauthor | You–Chen Chao | - |
dc.contributor.googleauthor | Kwang–Hyub Han | - |
dc.contributor.googleauthor | José Sollano | - |
dc.contributor.googleauthor | Adrian Gadano | - |
dc.contributor.googleauthor | Robert A. de Man | - |
dc.contributor.googleauthor | Ting–Tsung Chang | - |
dc.identifier.doi | 10.1053/j.gastro.2007.08.025 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A04268 | - |
dc.relation.journalcode | J00917 | - |
dc.identifier.eissn | 1528-0012 | - |
dc.identifier.pmid | 17983800 | - |
dc.identifier.url | http://www.sciencedirect.com/science/article/pii/S0016508507014825 | - |
dc.contributor.alternativeName | Han, Kwang Hyup | - |
dc.contributor.affiliatedAuthor | Han, Kwang Hyup | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 133 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 1437 | - |
dc.citation.endPage | 1444 | - |
dc.identifier.bibliographicCitation | GASTROENTEROLOGY, Vol.133(5) : 1437-1444, 2007 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.